Company intelligence / Profile preview
Shenzhen Turier Biotech
Shenzhen, Guangdong, Chinaturierbiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TB001 has completed Phase 1 studies demonstrating safety, tolerability, and pharmacokinetics in healthy subjects. It is now in or has completed Phase 2 trials targeting liver fibrosis. Preclinical research supports its efficacy as a GLP‑1R/GCGR dual agonist for hepatic fibrosis reversal.
- Therapeutic areas
- GastroenterologyPulmonology
- Modalities
- Synthetic peptideSmall molecule drugCyclic peptides
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Shenzhen Turier Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen Turier Biotech.